Accumulating evidence has firmly implicated a key role for SIRT3 deficiency in the pathobiology of IPF as well as the bleomycin murine model of lung fibrosis, but the detailed molecular mechanisms involved are not fully understood, nor is it known whether augmenting SIRT3 in mice following exposure to asbestos is protective [32,33,34,35,36,37,38,39]. The gene discussed is SIRT3; the disease is pulmonary fibrosis.